Carcinogenicity of estrogens in human breast epithelial cells

APMIS

Volumn 109, Issue 1, 2001, Pages 39-52

  Russo, Jose ^a   Hu, Yun Fu ^a,b   Tahin, Quivo ^a   Mihaila, Dana ^a   Slater, Carolyn ^a   Lareef, M Hasan ^a   Russo, Irma H ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Breast cancer; Carcinogenesis; Epithelial cells; Estrogens

Indexed keywords

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CELL TRANSFORMATION; CHROMOSOME 11Q; GENE AMPLIFICATION; HORMONAL CARCINOGENESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RISK FACTOR;

EID: 0035076735     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2001.tb00013.x     Document Type: Article

References (116)

1. Estrogens, progesterone, normal breast cell proliferation and breast cancer risk
2. Reproductive factors and breast cancer
3. Endogenous hormones and breast cancer risk
4. Estrogens as a cause of human cancer: The Richard & Hinda Rosenthal Foundation Award Lecture
5. Three stages of responsiveness to hormones in the mammary cell
6. Estrogens regulate production of specific growth factors in hormone-dependent human breast cancer
7. Menopausal estrogen replacement therapy and breast cancer
8. Predictors of breast cancer in women recall following screening
9. Estrogen receptor null mice: What have we learned and where will they lead us?
10. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
11. The molecular pharmacology of SERMs
12. Molecular mechanisms of steroid/thyroid receptor superfamily members
13. Dynamics of steroid hormone receptor action
14. ER β: Identification and characterization of a novel human estrogen receptor
15. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
16. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites
17. Activation of the estrogen-signaling pathway by p21 WAF1/CIP1 in estrogen receptor negative breast cancer cells
18. Cytochrome P-450-mediated redox cycling of estrogens
19. Temporary decrease in renal quinone and reductase activity induced by chronic administration of estradiol to male Syrian hamsters - Increased superoxide formation by redox cycling of estrogen
20. Mutations in DNA polymerase P mRNA of stilbene estrogen-induced kidney tumors in Syrian hamster
21. Catecholestrogens (2- and 4-hydroxy-oestrogens). Chemistry, biosynthesis, metabolism, occurrence and physiological significance
22. Conversion of estrone to 2- and 4- hydroxyestrone by hamster kidney and liver microsomes: Implications for the mechanism of estrogen-induced carcinogenesis
23. Microsomal hydroxylation of 2- and 4-fluoroestradiol to catechol metabolites and their conversion to methyl ethers: Catechol estrogens as possible mediators of hormonal carcinogenesis
24. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
25. Genetic alteration of the c-myc proto-oncogene (MYC) in human primary breast carcinomas
26. The amplification unit on chromosome 11 q13 in aggressive primary human breast tumors entails the bc1-1, int-2 and hst loci
27. BCL-1 participates in the 11q13 amplification found in breast cancer
28. Loss of a c-H-ras-1 and aggressive human primary breast carcinomas
29. Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13
30. Allele loss on short arm of chromosome 17 in breast cancers
31. Presence of two members of c-erbAB and c-erbA2 in smallest region of somatic homiozygosity on chromosome 3p21-p25 in human breast carcinoma
32. Loss of heterozygosity on chromosome 1q in human breast cancer
33. Mutations in human breast cancer: An overview
34. The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer
35. Heterogeneity for allelic loss in human breast cancer
36. Distal deletion of chromosome 1q in ductal carcinoma of the breast
37. Loss of heterozygosity on chromosomes 17 and 18 in breast carcinoma: Two additional regions identified
38. Allelotype of breast cancer: Cumulative allele losses promote tumor progression in primary breast cancer
39. Accumulation of genetic alterations and progression of primary breast cancer
40. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10
41. Ultrastructural and immunocytochemical characterizations of an immortalized human breast epithelial cell line MCF-10
42. Increased expression of estrogen receptor-β in chemically transformed human breast epithelial cells
43. Critical steps in breast carcinogenesis
44. Transformation of human breast epithelial cells by chemical carcinogens
45. A critical approach to the malignant transformation of human breast epithelial cells
46. C-Ha ras enhances the neoplastic transformation of human breast epithelial cells treated with chemical carcinogens
47. Deletion of two separate regions on chromosome 3p in breast cancers
48. Linkage analysis and allelic imbalance in human breast cancer kindreds using microsatellite markers from the short arm of chromosome 3
49. Multiple sites of loss of heterozygosity on chromosome arms 3p and 3q in human breast carcinomas
50. Deletion of the short arm of chromosome 3 in breast tumors
51. Highs level of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers
52. The FHIT gene at 3p14.2 is abnormal in breast carcinomas
53. Loss of a c-H-ras-I allele and aggressive human primary breast carcinomas
54. Partial deletion of chromosome 11p in breast cancer correlates with size of primary turnout and estrogen receptor level
55. Correlation of loss of alleles on the short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes
56. Refinement of regional loss of heterozygosity for chromosome 11p15.5 in human breast tumors
57. Loss of heterozygosity at chromosome 11 in breast cancer: Association of prognostic factors with genetic alterations
58. Seven-megabase yeast artificial chromosome contig at region 11p15: Identification of a yeast artificial chromosome spanning the breakpoint of a chromosomal translocation found in a case of Beckwith-Wiedmann syndrome
59. Loss of heterozygosity at 11 q22-q23 in breast cancer
60. Allelic deletions at chromosome 11q22-q23.1 and 11q25-q term are frequent in sporadic breast but not colorectal
61. Human DNA polymorphisms based on length variations in simple sequence tandem repeats
62. PCR of TG microsatellites
63. Informativeness of human (dC-dA)n (dG) n polymorphisms
64. Microsatellite Instability during the Immortalization and Transformation of Human Breast Epithelial Cells In vitro
65. An attempt to define sets of cooperating genetic alterations in human breast cancer
66. Accumulation of genetic alterations and progression of primary breast cancer
67. Loss of heterozygosity and p53 gene mutations in breast cancer
68. A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo
69. Definition of a tumor suppressor locus within human chromosome 3p21 -p22
70. Aberrant upregulation of a novel integrin α subunit gene at 3p21.3 in small cell lung cancer
71. Isolation from a multigene family of the active human gene of the metastasis-associated multifunctional protein 37LRP/p4O at chromosome 3p21.3
72. Role of laminin receptor in tumor cell migration
73. Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas
74. Are cellular adhesion molecules involved in metastasis of breast cancer
75. The gene for the APC-binding protein beta-catenin (CTNNB1) maps to chromosome 3p22, a region frequently altered in human malignancies
76. Chromosome abnormalities in benign hyper-proliferative disorders of epithelial and stromal breast tissue
77. New gene forges link between fragile site and many cancers
78. Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells
79. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions
80. Screening for germ line TP53 mutations in breast cancer patients
81. A highly polymorphic probe on 11p15.5: L22.5.2 (D11S774)
82. Mapping of the gene encoding the integrin-linked kinase, ILK, to human chromosome 11p15.5-p15.4
83. BRCA1 proteins arc transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases
84. KA/1, a metastasis suppressor gene for prostate cancer on human chromosome 11p1 1.2
85. Regulation of integrin function by the urokinase receptor
86. Losses of heterozygosity in sporadic human breast carcinoma: A common region between 11q22 and 11q23.3
87. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: Identification of a new region at 11 q23.3
88. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis
89. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice
90. Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle check-points
91. Incidence of cancer in 161 families affected by ataxia-telangiectasia
92. Identification and analysis of expression of human VACM-1, a cullin gene family member located on chromosome 11 q22-23
93. The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer
94. All ele loss on chromosome 11q and microsatellite instability in malignant melanoma
95. Identification of a region of frequent loss of heterozygosity at 11 q24 in colorectal cancer
96. Chromosome 11q22.3-q25 LOH in ovarian cancer: Association with a more aggressive disease course and involved subregions
97. Deletion of chromosome 1 1p15, p12, q22, q23-24 loci in human prostate cancer
98. Allelotype of colorectal carcinomas
99. Allelotype of breast cancer: Cumulative allele losses promote tumor progression in primary breast cancer
100. Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms
101. Genetics of human breast cancer
102. P53 mutations in human cancers
103. Evidence that p53 behaves as a tumor suppressor gene in sporadic breast tumors
104. Constant denaturant gel electrophoresis, a modification of denaturating gradient gel electrophoresis, in mutation detection
105. Mutations in the p53 gene in primary human breast cancers
106. P53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters
107. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas
108. Does a genotoxic carcinogen contribute to human breast cancer-7
109. Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancer
110. Human breast cancer: Frequent p53 allele loss and protein overexpression
111. Genetic alterations of the tumor suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas
112. Loss of heterozygosity on the shortarm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer
113. Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis
114. Breast cancer multistage progression
115. Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases
116. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread